Dyax enjoys climbing stock prices

Dyax had a great day Monday. The company released positive late-stage clinical trial findings regarding its drug DX-88 and investors took notice. According to its data, DX-88 reduced the symptoms associated with hereditary angioedema, a genetic blood disorder, and stocks climbed by 15.5 percent, to the company's 2008 peak thus far.  Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.